178 related articles for article (PubMed ID: 31693578)
1. Fibrodysplasia ossificans progressiva: lessons learned from a rare disease.
Akyuz G; Gencer-Atalay K; Ata P
Curr Opin Pediatr; 2019 Dec; 31(6):716-722. PubMed ID: 31693578
[TBL] [Abstract][Full Text] [Related]
2. The serum levels of activin A and bone morphogenetic protein-4 and -6 in patients with fibrodysplasia ossificans progressiva.
Ye Z; Wang S; Shan C; Zhu Q; Xue Y; Zhang K
Orphanet J Rare Dis; 2023 May; 18(1):111. PubMed ID: 37165433
[TBL] [Abstract][Full Text] [Related]
3. Fibrodysplasia ossificans progressiva: clinical and genetic aspects.
Pignolo RJ; Shore EM; Kaplan FS
Orphanet J Rare Dis; 2011 Dec; 6():80. PubMed ID: 22133093
[TBL] [Abstract][Full Text] [Related]
4. Rarely occurring mutation of ACVR1 gene in Moroccan patient with fibrodysplasia ossificans progressiva.
Ratbi I; Bocciardi R; Regragui A; Ravazzolo R; Sefiani A
Clin Rheumatol; 2010 Jan; 29(1):119-21. PubMed ID: 19795179
[TBL] [Abstract][Full Text] [Related]
5. The ACVR1 R206H mutation found in fibrodysplasia ossificans progressiva increases human induced pluripotent stem cell-derived endothelial cell formation and collagen production through BMP-mediated SMAD1/5/8 signaling.
Barruet E; Morales BM; Lwin W; White MP; Theodoris CV; Kim H; Urrutia A; Wong SA; Srivastava D; Hsiao EC
Stem Cell Res Ther; 2016 Aug; 7(1):115. PubMed ID: 27530160
[TBL] [Abstract][Full Text] [Related]
6. BMP signaling and skeletal development in fibrodysplasia ossificans progressiva (FOP).
Towler OW; Shore EM
Dev Dyn; 2022 Jan; 251(1):164-177. PubMed ID: 34133058
[TBL] [Abstract][Full Text] [Related]
7. Skeletal malformations and developmental arthropathy in individuals who have fibrodysplasia ossificans progressiva.
Towler OW; Shore EM; Kaplan FS
Bone; 2020 Jan; 130():115116. PubMed ID: 31655222
[TBL] [Abstract][Full Text] [Related]
8. Fibrodysplasia ossificans progressiva: middle-age onset of heterotopic ossification from a unique missense mutation (c.974G>C, p.G325A) in ACVR1.
Whyte MP; Wenkert D; Demertzis JL; DiCarlo EF; Westenberg E; Mumm S
J Bone Miner Res; 2012 Mar; 27(3):729-37. PubMed ID: 22131272
[TBL] [Abstract][Full Text] [Related]
9. The obligatory role of Activin A in the formation of heterotopic bone in Fibrodysplasia Ossificans Progressiva.
Alessi Wolken DM; Idone V; Hatsell SJ; Yu PB; Economides AN
Bone; 2018 Apr; 109():210-217. PubMed ID: 28629737
[TBL] [Abstract][Full Text] [Related]
10. Fibrodysplasia ossificans progressiva.
Kaplan FS; Le Merrer M; Glaser DL; Pignolo RJ; Goldsby RE; Kitterman JA; Groppe J; Shore EM
Best Pract Res Clin Rheumatol; 2008 Mar; 22(1):191-205. PubMed ID: 18328989
[TBL] [Abstract][Full Text] [Related]
11. A fibrodysplasia ossificans progressiva patient with a rare missense mutation in ACVR1 detected on
Ni H; Tang S; Zhang Y
Joint Bone Spine; 2024 Mar; 91(2):105682. PubMed ID: 38159793
[TBL] [Abstract][Full Text] [Related]
12. Identification of the Identical Human Mutation in
Casal ML; Engiles JB; Zakošek Pipan M; Berkowitz A; Porat-Mosenco Y; Mai W; Wurzburg K; Xu MQ; Allen R; ODonnell PA; Henthorn PS; Thompson K; Shore EM
Vet Pathol; 2019 Jul; 56(4):614-618. PubMed ID: 31007133
[TBL] [Abstract][Full Text] [Related]
13. Granting immunity to FOP and catching heterotopic ossification in the Act.
Kaplan FS; Pignolo RJ; Shore EM
Semin Cell Dev Biol; 2016 Jan; 49():30-6. PubMed ID: 26706149
[TBL] [Abstract][Full Text] [Related]
14. Classic and atypical fibrodysplasia ossificans progressiva (FOP) phenotypes are caused by mutations in the bone morphogenetic protein (BMP) type I receptor ACVR1.
Kaplan FS; Xu M; Seemann P; Connor JM; Glaser DL; Carroll L; Delai P; Fastnacht-Urban E; Forman SJ; Gillessen-Kaesbach G; Hoover-Fong J; Köster B; Pauli RM; Reardon W; Zaidi SA; Zasloff M; Morhart R; Mundlos S; Groppe J; Shore EM
Hum Mutat; 2009 Mar; 30(3):379-90. PubMed ID: 19085907
[TBL] [Abstract][Full Text] [Related]
15. Palovarotene Inhibits Heterotopic Ossification and Maintains Limb Mobility and Growth in Mice With the Human ACVR1(R206H) Fibrodysplasia Ossificans Progressiva (FOP) Mutation.
Chakkalakal SA; Uchibe K; Convente MR; Zhang D; Economides AN; Kaplan FS; Pacifici M; Iwamoto M; Shore EM
J Bone Miner Res; 2016 Sep; 31(9):1666-75. PubMed ID: 26896819
[TBL] [Abstract][Full Text] [Related]
16. Recent progress in drug development for fibrodysplasia ossificans progressiva.
Meng X; Wang H; Hao J
Mol Cell Biochem; 2022 Oct; 477(10):2327-2334. PubMed ID: 35536530
[TBL] [Abstract][Full Text] [Related]
17. Acute and chronic rapamycin use in patients with Fibrodysplasia Ossificans Progressiva: A report of two cases.
Kaplan FS; Zeitlin L; Dunn SP; Benor S; Hagin D; Al Mukaddam M; Pignolo RJ
Bone; 2018 Apr; 109():281-284. PubMed ID: 29241828
[TBL] [Abstract][Full Text] [Related]
18. Fibrodysplasia ossificans progressiva (FOP): A disorder of osteochondrogenesis.
Kaplan FS; Al Mukaddam M; Stanley A; Towler OW; Shore EM
Bone; 2020 Nov; 140():115539. PubMed ID: 32730934
[TBL] [Abstract][Full Text] [Related]
19. Overexpression of Wild-Type ACVR1 in Fibrodysplasia Ossificans Progressiva Mice Rescues Perinatal Lethality and Inhibits Heterotopic Ossification.
Yamamoto M; Stoessel SJ; Yamamoto S; Goldhamer DJ
J Bone Miner Res; 2022 Nov; 37(11):2077-2093. PubMed ID: 35637634
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]